Hanadie Yousef, PhD
CEO and Co-Founder
Dr. Hanadie Yousef is a leading expert on the biology of aging and mechanisms underlying tissue degeneration. A scientific pioneer with two decades experience in biomedical research, she is the co-founder and CEO of Juvena Therapeutics, a venture-backed biotechnology company mapping the therapeutic potential of secreted proteins to develop biologics that prevent, reverse and cure chronic and age-related diseases.
Dr. Yousef’s high-impact published research has been supported by fellowships and grants from the National Institute of Health (NIH), National Science Foundation (NSF), SPARK at Stanford, and the California Institute for Regenerative Medicine (CIRM) and led to multiple issued and pending patents. Under Dr. Yousef’s leadership, Juvena has secured nearly $50M since launching in 2018 and developed a proprietary pro-regenerative protein library supported by an artificial intelligence-enabled drug discovery and development platform.
The platform has enabled the identification, extensive preclinical validation, and lead optimization of three novel drug candidates, as well as discovery candidates for several chronic and age-related degenerative diseases.
Dr. Yousef earned her B.S. in Chemistry with a Spanish minor, summa cum laude from Carnegie Mellon University and a PhD in Molecular and Cell Biology from UC Berkeley as an NSF graduate research fellow. She pursued a 5-year postdoctoral fellowship in Neurology at Stanford School of Medicine as an NIH fellow and SPARK scholar. Her early research began at Regeneron and Genentech.
Learn More about Hanadie
Jeremy O’Connell, PhD
Chief Scientific Officer and Co-Founder
As Chief Scientific Officer and Co-Founder of Juvena Therapeutics, Dr. O’Connell oversees research strategy, pre-clinical science and manufacturing, and intellectual property efforts. Dr. O’Connell’s expertise in proteomics and systems biology expert accrued during a PhD from UT Austin, a postdoc at Harvard, and his time in industry.
Prior to Juvena Therapeutics, in his postdoctoral fellowship at Harvard Medical school in the lab of Steven Gygi, he leveraged large proteomics datasets to build machine learning classifiers to improve protein-protein interaction predictions within the ubiquitin system.
He has spearheaded research projects in multiple tier-one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imaging, and computational approaches. His work has resulted in numerous peer-reviewed publications, approved and pending patents, millions in award grant funding as the primary PI, fellowships, and awards.
Learn more about Jeremy
Stephen Juelsgaard, DVM, JD
Former EVP Genentech
Stephen Juelsgaard is the former executive vice president, secretary and chief compliance officer of Genentech, Inc. His career at Genentech spanned 24 years. In that role, Dr. Juelsgaard reported to Genentech’s CEO, Art Levinson, and was responsible for Genentech’s Corporate Law, Intellectual Property, Government Affairs (Federal and State), Human Resources, and Healthcare Compliance groups, as well as the Business Services group, which included Strategic Facilities Planning, Corporate Security, Business Continuity, and Environment, Health & Safety. He also chaired Genentech’s Capital Governance Committee, which oversaw major capital expenditures at the company, and was a member of Genentech’s executive committee, the most senior management committee at the company. He had oversight responsibility for more than 600 employees and an annual budget of approximately $250 million.
Juelsgaard joined Genentech in 1985 as corporate counsel and became senior corporate counsel in 1989. In 1992 he became vice president, Corporate Law and in 1994 was named general counsel, a role he served in through 2007. Juelsgaard was named secretary to the Board of Directors in 1997 and a senior vice president in 1998. In 2002, he was appointed executive vice president, in 2005 was named chief compliance officer, and in 2007 he became responsible for oversight of the Government Affairs group. Juelsgaard was the company’s representative on the board of directors of the California Healthcare Institute from 2005 until 2009.
Prior to joining Genentech, Juelsgaard was an associate for three years with the law firm Wilson Sonsini Goodrich & Rosati in Palo Alto, California. Prior to attending law school, Juelsgaard was engaged for three years in a private veterinary medical practice.
Juelsgaard currently teaches at the Stanford Law School. He currently serves on the board of directors of Altrubio, an antibody-drug conjugate company targeting a variety of autoimmune and immune-mediated inflammatory diseases. He is a past member of the board of directors of Ivivi Health Sciences LLC, a private medical device company, and of Rio Grande Neurosciences, Inc., a private company engaged in the development of pulsed electromagnetic field technology as well as transcranial electrical stimulation and transcranial magnetic stimulation technologies.
Juelsgaard received his Doctor of Veterinary Medicine degrees from Iowa State University in 1972 and a Masters Degree in Veterinary Clinical Sciences in 1975 from Iowa State University, and in 1982 he received a law degree from Stanford Law School.
Learn more about Stephen
Dr. Hannoush is a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. He focuses on early-stage biotechnology investments, and also leads the firm’s efforts in life sciences company creation. Prior to his current position, Dr. Hannoush spent fifteen years at Genentech where he was a Senior Group Leader, and he led both early- and late-stage discovery biology programs in Ophthalmology, Immunology and Oncology, with a focus on drug discovery and development, as well as target discovery and validation.
His former Laboratory in translational biology at Genentech focused on new drug modalities and understanding the role of protein – protein interactions in stem cell signaling pathways for cellular reprogramming and tissue regeneration, and his group made important contributions in the fields of Wnt signaling and protein lipidation. He obtained his PhD in Chemistry from McGill University and did his postdoctoral training in chemical biology and cell biology at Harvard.